Bulletin
Investor Alert

Deciphera Pharmaceuticals Inc.

NAS: DCPH

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Deciphera Pharmaceuticals Inc.

After Hours

 --Quotes are delayed by 20 min

Jan 28, 2022, 5:55 p.m.

DCPH
/zigman2/quotes/203556943/composite

$

7.56

Change

-0.22 -2.83%

Volume

Volume 390,877

Quotes are delayed by 20 min

/zigman2/quotes/203556943/composite

Previous close

$ 7.72

$ 7.78

Change

+0.06 +0.78%

Day low

Day high

$7.36

$7.85

Open

52 week low

52 week high

$7.36

$52.43

Open

Company Description

Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastr...

Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.

Valuation

Price to Sales Ratio

75.64

Price to Book Ratio

6.05

Enterprise Value to EBITDA

0.26

Enterprise Value to Sales

-0.76

Total Debt to Enterprise Value

0.01

Efficiency

Revenue/Employee

120,249.00

Income Per Employee

-761,397.00

Receivables Turnover

6.06

Total Asset Turnover

0.07

Liquidity

Current Ratio

8.34

Quick Ratio

8.26

Cash Ratio

7.89

Profitability

Gross Margin

87.25

Operating Margin

-644.36

Pretax Margin

-633.19

Net Margin

-633.19

Return on Assets

-42.14

Return on Equity

-48.89

Return on Total Capital

-47.62

Return on Invested Capital

-46.97

Capital Structure

Total Debt to Total Equity

5.74

Total Debt to Total Capital

5.43

Total Debt to Total Assets

4.86

Long-Term Debt to Equity

5.29

Long-Term Debt to Total Capital

5.00

Officers and Executives

Name Age Officer Since Title
Mr. Steven L. Hoerter 49 - President, Director & Chief Executive Officer
Mr. Thomas P. Kelly 49 2015 Chief Financial Officer
Dr. Matthew L. Sherman 64 2019 Chief Medical Officer & Executive Vice President
Dr. Daniel L. Flynn 66 - President, Chief Executive Officer & Director
Dr. Stephen B. Ruddy 56 2018 Chief Technical Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
01/18/2022 Daniel L. Flynn
Chief Scientific Officer 		20,500   Award at $0 per share. 0
01/18/2022 Matthew L. Sherman
EVP & Chief Medical Officer 		20,500   Award at $0 per share. 0
01/18/2022 Daniel C. Martin
Chief Commercial Officer 		13,667   Award at $0 per share. 0
01/18/2022 Thomas P. Kelly
Chief Financial Officer 		20,500   Award at $0 per share. 0
01/18/2022 Jama Pitman
See Remarks 		13,667   Award at $0 per share. 0
12/15/2021 Daniel L. Flynn
Chief Scientific Officer 		11,100   Award at $0 per share. 0
12/15/2021 Matthew L. Sherman
EVP & Chief Medical Officer 		11,100   Award at $0 per share. 0
12/15/2021 Daniel C. Martin
Chief Commercial Officer 		8,300   Award at $0 per share. 0
12/15/2021 Thomas P. Kelly
Chief Financial Officer 		11,100   Award at $0 per share. 0
12/15/2021 Jama Pitman
See Remarks 		8,300   Award at $0 per share. 0
10/04/2021 Matthew L. Sherman
EVP & Chief Medical Officer 		2,659   Disposition at $33.17 per share. 88,199
05/03/2021 Michael D. Taylor
Director 		300   Disposition at $46.75 per share. 14,025
05/03/2021 Michael D. Taylor
Director 		7,700   Disposition at $46.07 per share. 354,739
05/03/2021 Michael D. Taylor
Director 		5,646   Derivative/Non-derivative trans. at $3.95 per share. 22,301
05/03/2021 Michael D. Taylor
Director 		2,354   Derivative/Non-derivative trans. at $1.89 per share. 4,449
04/20/2021 James A. Bristol
Director 		1,700   Disposition at $45.6 per share. 77,520
04/20/2021 James A. Bristol
Director 		1,700   Derivative/Non-derivative trans. at $3.95 per share. 6,715
04/19/2021 James A. Bristol
Director 		1,300   Disposition at $46.66 per share. 60,658
04/19/2021 James A. Bristol
Director 		4,000   Disposition at $46.13 per share. 184,520
04/19/2021 James A. Bristol
Director 		5,300   Derivative/Non-derivative trans. at $3.95 per share. 20,935
04/12/2021 James A. Bristol
Director 		5,217   Disposition at $44.09 per share. 230,017
04/12/2021 James A. Bristol
Director 		9,483   Disposition at $43.7 per share. 414,407
04/12/2021 James A. Bristol
Director 		14,700   Derivative/Non-derivative trans. at $3.95 per share. 58,065
04/01/2021 Michael D. Taylor
Director 		906   Disposition at $46.72 per share. 42,328
04/01/2021 Michael D. Taylor
Director 		4,994   Disposition at $45.69 per share. 228,175
04/01/2021 Michael D. Taylor
Director 		2,100   Disposition at $44.8 per share. 94,080
04/01/2021 Michael D. Taylor
Director 		8,000   Derivative/Non-derivative trans. at $1.89 per share. 15,120
03/18/2021 Steven L. Hoerter
President and CEO; Director 		2,450   Derivative/Non-derivative trans. at $43.19 per share. 105,815
03/18/2021 Steven L. Hoerter
President and CEO; Director 		700   Derivative/Non-derivative trans. at $42.39 per share. 29,673
03/01/2021 Michael D. Taylor
Director 		1,104   Disposition at $44.68 per share. 49,326
03/01/2021 Michael D. Taylor
Director 		6,896   Disposition at $43.94 per share. 303,010
03/01/2021 Michael D. Taylor
Director 		8,000   Derivative/Non-derivative trans. at $1.89 per share. 15,120
/news/latest/company/us/dcph

MarketWatch News on DCPH

  1. Deciphera Pharmaceuticals downgraded to hold from buy at Truist

    8:04 a.m. Nov. 8, 2021

    - Tomi Kilgore

  2. Deciphera Pharmaceuticals downgraded to hold from buy at Stifel Nicolaus

    7:58 a.m. Nov. 8, 2021

    - Tomi Kilgore

  3. Deciphera Pharmaceuticals stock price target cut to $65 from $84 at Truist

    6:16 a.m. Oct. 4, 2021

    - Tomi Kilgore

  4. Deciphera Pharmaceuticals coverage resumed at Stifel with buy stock rating and $60 target price

    6:05 a.m. Sept. 30, 2021

    - Tonya Garcia

  5. Deciphera Pharmaceuticals started at buy with $75 stock price target at Stifel Nicolaus

    9:16 a.m. Dec. 3, 2020

    - Tomi Kilgore

  6. Callon, Fitbit, Genco Shipping, and Other 13D Filings

    9:30 p.m. Nov. 22, 2019

    - Barron's Online

  7. Deciphera Pharmaceuticals stock price target raised to $60 from $45 at SunTrust RH

    7:40 a.m. Aug. 14, 2019

    - Tomi Kilgore

  9. Deciphera Pharmaceuticals stock rockets 126% premarket after positive trial data for GIST treatment

    7:32 a.m. Aug. 13, 2019

    - Tomi Kilgore

  10. Deciphera Pharmaceuticals started at buy with $42 stock price target at Deutsche Bank

    1:17 p.m. July 18, 2019

    - Tomi Kilgore

  11. Deciphera Pharmaceuticals started at outperform with $47 stock price target at Raymond James

    7:25 a.m. Aug. 29, 2018

    - Tomi Kilgore

  12. Deciphera Pharmaceuticals started at buy with $60 stock price target at SunTrust RH

    6:54 a.m. July 5, 2018

    - Tomi Kilgore

  13. Deciphera Pharmaceuticals started at overweight with $30 stock price target at J.P. Morgan

    6:40 a.m. Oct. 23, 2017

    - Tomi Kilgore

/news/nonmarketwatch/company/us/dcph

Other News on DCPH

  11. Why Deciphera Pharmaceuticals Shot 12% Higher Today

    6:11 p.m. Nov. 30, 2021

    - Motley Fool

  18. SQM, VSTM and TGB among pre market gainers

    8:24 a.m. Nov. 22, 2021

    - Seeking Alpha

  19. Warning: DCPH is at high risk of performing badly

    5:07 a.m. Nov. 9, 2021

    - Seeking Alpha

  20. Deciphera slapped with downgrades after trial disappointment

    8:37 a.m. Nov. 8, 2021

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Deciphera Pharmaceuticals, Inc.

200 Smith Street

Waltham, Massachusetts 02451

Phone

1 7812096400

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

View SEC Filings

Revenue

$42.09M

Net Income

$-266.49M

2020 Sales Growth

68.3%

Employees

350.00

Annual Report for DCPH

/news/pressrelease/company/us/dcph

Press Releases on DCPH

  10. Mission BioCapital Announces $275 Million Fund V

    5:00 a.m. Nov. 4, 2021

    - BusinessWire - BZX

  21. Loading more headlines...
Link to MarketWatch's Slice.